Ulcerative Colitis

Significant need remains in ulcerative colitis



MH002 for treatment of Ulcerative Colitis and beyond

MH002 is an orally administered Optimized Consortium, consisting of 6 rationally selected commensal bacteria and designed to repair multiple key disease-modifying mechanisms in Inflammatory Bowel Diseases. MH002 is in Phase Ib/2a clinical development for treatment of mild-to-moderate Ulcerative Colitis, with a second clinical program in preparation for a specific niche indication within the IBD field.

Unmet needs in IBD

  • Approximately 10 million patients worldwide are diagnosed with IBD and the prevalence has been increasing over the last two decades.
  • Disease symptoms include diarrhea, abdominal pain and rectal bleeding.
  • Current treatment options are limited to symptomatic treatment and ineffective for many IBD patients.
  • Gut microbiome dysbiosis is seen as a core problem in IBD, leading to dysregulated immune responses
  • Microbiome therapeutics represent a safe, novel approach with potential for immune regulation and disease-modifying activity.
  • microbiome therapeutics Ulceretive colitis Crohn's disease treatment IBD

    MH002 as novel treatment for IBD

    - Optimized Consortium of 6 rationally selected commensal bacteria, with differentiation from current standard of care through its mode-of-action and excellent safety profile.
    - Repairs microbiome dysbiosis and intestinal barrier, restores immune homeostasis.
    - Optimized consortia technology: increased potency, engraftment, and resilience.
    - Convenient once daily oral administration
    - Manufactured with our scalable and cost-effective single drug substance technology.
    - Phase 1b/2a study in UC and extension into niche indication ongoing.
    - Strong IP position with 2 granted patents.